How herpes simplex virus changes cell DNA-repair and protein systems

Manipulation of the DNA damage response and the proteome on viral genomes during Herpes Simplex Virus (HSV) infection

NIH-funded research Children's Hosp of Philadelphia · NIH-11231732

This work looks at how herpes simplex virus (HSV) hijacks cells' DNA-repair and protein-handling systems to help the virus, with the goal of informing better treatments for people with HSV infections.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionChildren's Hosp of Philadelphia NIH-funded
Lab location1 site (Philadelphia, United States)
Project IDNIH-11231732 on NIH RePORTER

What this research studies

Researchers will use broad proteomics and signaling-mapping methods to see how HSV infection and the viral protein ICP0 alter the cell's DNA damage response and proteasome activity. Most experiments will be done in infected cells in the lab to identify which host proteins are modified, degraded, or moved during infection. The team focuses on signaling and protein changes specifically at viral genomes rather than only on damaged cellular DNA. By creating an unbiased map of these interactions, the study aims to reveal cellular pathways that could be targeted to prevent or limit HSV replication.

Who could benefit from this research

Good fit: People with recurrent or severe HSV-1 infections who want improved antiviral options would be the most likely to benefit from findings that lead to new therapies.

Not a fit: People without herpes simplex infections or those with unrelated viral illnesses are unlikely to benefit directly from this basic laboratory research.

Why it matters

Potential benefit: If successful, the work could reveal new molecular targets for antiviral drugs or strategies to reduce HSV replication.

How similar studies have performed: Prior laboratory studies have shown HSV uses DNA damage response pathways and the ICP0 protein to promote replication, but applying broad proteomics to map signaling on viral genomes is a newer approach that may reveal additional targets.

Where this research is happening

Philadelphia, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.